{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:47:41Z","timestamp":1766551661634,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA90338-27"],"award-info":[{"award-number":["T32CA90338-27"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bruton\u2019s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in this process. Understanding the potential mechanism of action of BTK inhibition in SARS-CoV-2 is clearly of importance to determine how acalabrutinib, ibrutinib and possibly other BTK inhibitors may provide protection against lung injury.<\/jats:p>","DOI":"10.1186\/s13045-020-00999-8","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T15:04:04Z","timestamp":1610550244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Observations on the use of Bruton\u2019s tyrosine kinase inhibitors in SAR-CoV-2 and cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Brooke","family":"Benner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"999_CR1","doi-asserted-by":"crossref","unstructured":"Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020; http:\/\/www.nature.com\/articles\/s41586-020-2312-y","DOI":"10.1101\/2020.02.07.939389"},{"key":"999_CR2","doi-asserted-by":"crossref","unstructured":"Sungnak W, Huang N, B\u00e9cavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020; http:\/\/www.nature.com\/articles\/s41591-020-0868-6","DOI":"10.1038\/s41591-020-0868-6"},{"key":"999_CR3","doi-asserted-by":"crossref","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; http:\/\/www.nature.com\/articles\/s41577-020-0331-4","DOI":"10.1038\/s41577-020-0331-4"},{"issue":"4","key":"999_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","volume":"388","author":"H Kumar","year":"2009","unstructured":"Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009;388(4):621\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"999_CR5","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.","journal-title":"Int J Mol Sci"},{"key":"999_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00050\/full","author":"I-Y Chen","year":"2019","unstructured":"Chen I-Y, Moriyama M, Chang M-F, Ichinohe T. Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019. https:\/\/doi.org\/10.3389\/fmicb.2019.00050\/full.","journal-title":"Front Microbiol"},{"issue":"8","key":"999_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, et al. Myeloid-derived suppressor cells express bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 2016;76(8):2125\u201336.","journal-title":"Cancer Res"},{"key":"999_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1659704","author":"B Benner","year":"2019","unstructured":"Benner B, Scarberry L, Stiff A, Duggan MC, Good L, Lapurga G, et al. Evidence for interaction of the NLRP3 inflammasome and Bruton\u2019s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta. Oncoimmunology. 2019. https:\/\/doi.org\/10.1080\/2162402X.2019.1659704.","journal-title":"Oncoimmunology."},{"issue":"1","key":"999_CR9","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","volume":"6","author":"M Ito","year":"2015","unstructured":"Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, et al. Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6(1):7360.","journal-title":"Nat Commun"},{"issue":"5","key":"999_CR10","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest [Internet]. 2020;130(5):2620\u20139.","journal-title":"J Clin Invest [Internet]"},{"issue":"10223","key":"999_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497\u2013506.","journal-title":"China Lancet"},{"key":"999_CR12","doi-asserted-by":"publisher","unstructured":"Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110. https:\/\/doi.org\/10.1126\/sciimmunol.abd0110","DOI":"10.1126\/sciimmunol.abd0110"},{"issue":"3","key":"999_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.2067","volume":"210","author":"L He","year":"2006","unstructured":"He L, Ding Y, Zhang Q, Che X, He Y, Shen H, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2 + cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210(3):288\u201397. https:\/\/doi.org\/10.1002\/path.2067.","journal-title":"J Pathol"},{"issue":"2","key":"999_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s12013-014-0050-1","volume":"70","author":"P Zhou","year":"2014","unstructured":"Zhou P, Ma B, Xu S, Zhang S, Tang H, Zhu S, et al. Knockdown of Burton\u2019s tyrosine kinase confers potent protection against sepsis-induced acute lung injury. Cell Biochem Biophys. 2014;70(2):1265\u201375. https:\/\/doi.org\/10.1007\/s12013-014-0050-1.","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"999_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10020-018-0069-7","volume":"25","author":"AP de Porto","year":"2019","unstructured":"de Porto AP, Liu Z, de Beer R, Florquin S, de Boer OJ, Hendriks RW, et al. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia. Mol Med. 2019;25(1):3. https:\/\/doi.org\/10.1186\/s10020-018-0069-7.","journal-title":"Mol Med"},{"issue":"1","key":"999_CR16","doi-asserted-by":"publisher","first-page":"L52","DOI":"10.1152\/ajplung.00047.2018","volume":"315","author":"JM Florence","year":"2018","unstructured":"Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton\u2019s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Cell Mol Physiol. 2018;315(1):L52\u20138. https:\/\/doi.org\/10.1152\/ajplung.00047.2018.","journal-title":"Am J Physiol Cell Mol Physiol"},{"key":"999_CR17","doi-asserted-by":"crossref","unstructured":"Treon SP, Castillo JJ, Skarbnik AP, Soumerai J, Ghobrial IM, Guerrera ML, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020;","DOI":"10.1182\/blood.2020006288"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-020-00999-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T12:16:18Z","timestamp":1670760978000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00999-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00999-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"type":"electronic","value":"1756-8722"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}